RNA Therapeutics Platform
Cancer
Pre-clinical/PlatformActive
Key Facts
About Pendrea Bio
Pendrea Bio is an innovative, early-stage biotech leveraging proprietary nanoparticle platforms to create novel cancer treatments with dual mechanisms of action. Its lead asset, Ceraxa, has completed Phase 1 and shows promise in restoring chemotherapeutic efficacy and enhancing immuno-oncology agents. The company's pipeline also includes the light-activated PINT platform and a flexible RNA delivery system, positioning it at the intersection of drug delivery, immunotherapy, and gene therapy for oncology.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |